增量血液透析的叙述性综述
本文综述初发终末期肾病患者增量血液透析的潜在获益与障碍,指出从非透析慢性肾脏病直接转为每周三次中心透析忽视肾功能渐进下降过程,残余肾功能联合辅助药物治疗可支持较低强度起始方案,阶梯式从每周两次过渡至每周三次或可标准化增量透析,但需临床试验严格评估依从性与生存等结局。
要点
- 残余肾功能联合利尿剂、酸缓冲剂、钾结合剂可补充低强度起始透析
- 增量透析障碍包括残余肾功能不可预测丢失致清除不足、依从性差与财务负担
- 阶梯式每周两次转每周三次方案需临床试验严格评估后再推广
核心结论
- 初发终末期肾病采用较低强度起始透析并以残余肾功能和辅助药物补充具有理论合理性,阶梯式增量方案需临床试验验证后方可大规模实施。
研究设计与样本
- 叙述性综述,讨论初发终末期肾病患者替代透析方案的获益与障碍,并总结正在进行的增量血液透析方案临床试验。
主要发现
- 从非透析慢性肾脏病直接转为与 prevalent ESKD 相同强度的每周三次中心透析,忽视了肾功能渐进且持续下降的特点。
- 辅助药物治疗联合残余肾功能可补充较低强度的初始透析方案。
- 阶梯式定时从每周两次透析过渡至每周三次透析,可能成为标准化增量透析的有效安全策略。
临床怎么用
- 对初发终末期肾病患者可考虑较低强度起始透析,以残余肾功能联合利尿剂、酸缓冲剂、钾结合剂补充,并按计划阶梯式增加透析频率。
局限性
- 残余肾功能可变且不可预测地丢失,可能导致尿毒症毒素清除不足。
- 患者对残余肾功能评估或透析强度调整的依从性不足,透析单位各方负担增加并有负面财务影响。
- 不同增量透析方案的依从性、生存及其他临床结局尚需临床试验严格评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prescription of hemodialysis (HD) in patients with incident end-stage kidney disease (ESKD) is fundamentally empirical. The abrupt transition from nondialysis chronic kidney disease (CKD) to thrice-weekly in-center HD of much the same dialysis intensity as in those with prevalent ESKD underappreciates the progressive nature of kidney disease whereby the decline in renal function has been gradual and ongoing-including at the time of HD initiation. Adjuvant pharmacologic treatment (i.e., diuretics, acid buffers, potassium binders), coupled with residual kidney function (RKF), can complement an initial HD regimen of lower intensity. Barriers to less intensive HD in incident ESKD include risk of inadequate clearance of uremic toxins due to variable and unexpected loss of RKF, lack of patient adherence to assessments of RKF or adjustment of HD intensity, increased burden for all stakeholders in the dialysis units, and negative financial repercussions. A stepped dialysis regimen with scheduled transition from time-delineated twice-weekly HD to thrice-weekly HD could represent an effective and safe strategy to standardize incremental HD in patients with CKD transitioning to early-stage ESKD. Patients' adherence and survival as well as other clinical outcomes should be rigorously evaluated in clinical trials before large-scale implementation of different incremental schedules of HD. This review discusses potential benefits of and barriers to alternative dialysis regimens in patients with incident ESKD, with emphasis on twice-weekly HD with pharmacologic therapy, and summarizes in-progress clinical trials of incremental HD schedules.
引用
- Murea M, Moossavi S, Garneata L, et al. Narrative Review of Incremental Hemodialysis. Kidney Int Rep. 2019. PMID: 32043027. doi:10.1016/j.ekir.2019.11.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。